Clinical Trials
39 trialsMK-3475-06F
Merck Sharp & Dohme LLC
MK-3475-06B
Merck Sharp & Dohme LLC
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
Terremoto Biosciences Inc.
A Study of IDP-001 in Advanced or Metastatic Solid Tumors
InduPro, Inc.
MK-3475-06E
Merck Sharp & Dohme LLC
BetaBart
Radiopharm Theranostics, Ltd
Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors
Hoffmann-La Roche
A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors
Alentis Therapeutics AG
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Neonc Technologies, Inc.
Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination
Merus B.V.
S095033 in Combination With Paclitaxel as 2nd- or 3rd-line Treatment in Participants With Advanced or Metastatic ESCC
Servier
A Prospective, Multicenter, Phase Ib/II Trial of Ivonescimab (AK112) Combined With Albumin-Paclitaxel and Cisplatin as Neoadjuvant Therapy for ESCC
Tang-Du Hospital
A Study of Combination Therapies With or Without Pembrolizumab (MK-3475) and/or Chemotherapy in Participants With Advanced Esophageal Cancer (MK-3475-06A)
Merck Sharp & Dohme LLC
Oncolytic Virus in Esophageal Squamous Cell Carcinoma
Sichuan University
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
DualityBio Inc.
Clinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors
Yuhan Corporation
RAPA-201 Therapy of Solid Tumors
Rapa Therapeutics LLC
APT-CUBE
AP Biosciences Inc.
Efficacy and Safety of QL1706 Plus Lenvatinib As 2nd Line Theapy in Patients with Metastatic Esophageal Carcinoma After Disease Progression on ICIs Therapy
The First Affiliated Hospital of Zhengzhou University
JAB-3068 Activity in Adult Patients With Advanced Solid Tumors
Jacobio Pharmaceuticals Co., Ltd.
Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer
Ludwig Institute for Cancer Research
CRIS
Zhejiang Cancer Hospital
Immunotherapy in Combination With Chemoradiotherapy in Unresectable Locally Advanced Esophageal Cancer
Shanghai Chest Hospital
Fruquintinib as First Line Treatment in Patients With Recurrent Esophageal Squamous Cell Carcinoma
The First Affiliated Hospital with Nanjing Medical University
Z650 in Advanced Esophageal Squamous Cell Carcinoma With EGFR Over Expression or Gene Amplification
Sunshine Lake Pharma Co., Ltd.
Pembrolizumab Plus CRT Followed by Surgery in Upper ESCC
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
LATE
Jiangsu Cancer Institute & Hospital
Immune Checkpoint Therapy With Nivolumab Esophageal Squamous Cell Carcinoma
NYU Langone Health
Camrelizumab in Combination With Neoadjuvant Chemotherapy for Resectable Thoracic Esophageal Squamous Cell Carcinoma
Zhejiang Cancer Hospital
The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC
Shanghai Junshi Bioscience Co., Ltd.
A Phase I/II Study of Oblimersen Plus Cisplatin and Fluorouracil in Gastric & Esophageal Junction Cancer
National Cancer Institute (NCI)
Safety and Efficacy of SCT200 in Patients With Advanced Esophageal Squamous Cell Carcinoma
Sinocelltech Ltd.
ARTEMIS-Eso
Jules Bordet Institute
Fluorouracil, Cisplatin, Cetuximab, and Radiation Therapy in Treating Patients With Esophageal Cancer That Can Be Removed by Surgery
Federation Francophone de Cancerologie Digestive
Oxaliplatin, Gefitinib, and Radiation Therapy in Treating Patients With Locally Advanced or Metastatic Esophageal Cancer
Roswell Park Cancer Institute
Cetuximab, Oxaliplatin, Fluorouracil, and Radiation Therapy in Treating Patients With Stage II or Stage III Esophageal Cancer
Technical University of Munich
Study of Nimotuzumab to Treat Esophageal Squamous Cell Carcinoma.
Peking University
Cetuximab, Docetaxel, Cisplatin, and Radiation Therapy in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed by Surgery
Swiss Cancer Institute
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced or Metastatic Cancer of the Esophagus
UNC Lineberger Comprehensive Cancer Center